10561328

research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 14:27:44 ON 18 JAN 2007

=> fil reg

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.21	0.21

FILE 'REGISTRY' ENTERED AT 14:27:55 ON 18 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 17 JAN 2007 HIGHEST RN 917745-84-7
DICTIONARY FILE UPDATES: 17 JAN 2007 HIGHEST RN 917745-84-7

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/ONLINE/UG/regprops.html

=>
Uploading C:\Program Files\Stnexp\Queries\10561328.str





chain nodes :
6 7 8 9 10 11
ring nodes :
1 2 3 4 5
chain bonds :
1-11 4-6 5-10 6-7 7-8 7-9
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :

Karen Cheng

10561328

1-2 1-5 2-3 3-4 4-5 4-6 5-10 6-7 7-8 7-9
exact bonds :
1-11

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 6:CLASS 7:CLASS 8:CLASS 9:CLASS
10:CLASS 11:Atom

L1 STRUCTURE UPLOADED

=> d
L1 HAS NO ANSWERS
L1 STR



Structure attributes must be viewed using STN Express query preparation.

=> s l1 full
FULL SEARCH INITIATED 14:28:12 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 3058 TO ITERATE

100.0% PROCESSED 3058 ITERATIONS 383 ANSWERS
SEARCH TIME: 00.00.01

L2 383 SEA SSS FUL L1

=> fil caplus
COST IN U.S. DOLLARS SINCE FILE ENTRY TOTAL SESSION
FULL ESTIMATED COST 172.10 172.31

FILE 'CAPLUS' ENTERED AT 14:28:18 ON 18 JAN 2007
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2007 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching

Karen Cheng

10561328

databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 18 Jan 2007 VOL 146 ISS 4
FILE LAST UPDATED: 17 Jan 2007 (20070117/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

http://www.cas.org/infopolicy.html

=> s l2
L3 16 L2

=> d ibib abs hitstr tot

Karen Cheng

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2006:236680 CAPLUS
DOCUMENT NUMBER: 144:311901
TITLE: Preparation of N-[1-(2,3-dihydro-1H-inden-5-yl)-2-oxo-3-pyrrolidinyl] sulfonamides as Factor Xa inhibitors
INVENTOR(S): Harling, John David; Kleanthous, Savvas; Watson, Nigel
Stephen; West, Robert Ian; Young, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 61 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2006027186	A1	20060316	WO 2005-EP9517	20050902

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM

PRIORITY APPLN. INFO.: GB 2004-19744 A 20040906

OTHER SOURCE(S): MARPAT 144:311901
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title compds. I [R1 = II-VII (wherein each ring optionally contains a further heteroatom N; Z = optional substituent halogen; alk = alkylene or alkenylene; T = S, O or NH); R2 = H, alkyl, alkyl(CONRaRb), alkylCO2(alkyl), CO2(alkyl) or alkyl(CO2H); Ra, Rb = H, alkyl, or together with the N atom to which they are bonded form a 5-7 membered non-aromatic heterocyclic ring optionally containing an addnl. heteroatom selected from O, N and S; n = 0-2; X = an optional substituent on the indane ring selected from halo, alkyl, alkenyl and CF3; Y = (CH2)mNRcRd ; Rc, Rd = H, alkyl, alkyl(OH), or together with the N atom to which they are bonded form a 4-7 membered non-aromatic heterocyclic ring; m = 0-2; and pharmaceutically acceptable derivative(s) thereof], useful as Factor Xa inhibitors, were prepared

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



● HCl

RN 879499-81-7 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 879499-82-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879499-83-9 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
E.g., a multi-step synthesis of VIII.HCl, starting from 5-aminoindan-1-one, was given. All exemplified compds. I were found to exhibit Factor Xa inhibitory activity (Ki of <0.1 μM). The invention also relates to processes for the prepn. of compds. I, pharmaceutical compns. contg. compds. I and to the use of compds. I in medicine, particularly in the amelioration of a clin. condition for which a Factor Xa inhibitor is indicated.

IT 879499-79-3P 879499-80-6P 879499-81-7P
879499-82-8P 879499-83-9P 879499-84-0P
879499-85-1P 879499-86-2P 879499-87-3P
879499-88-4P 879499-89-5P 879499-90-8P
879500-18-2P 879500-20-6P 879500-21-7P
879500-22-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of N-[1-(2,3-dihydro-1H-inden-5-yl)-2-oxo-3-pyrrolidinyl] sulfonamides as Factor Xa inhibitors)

RN 879499-79-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-, monohydrochloride (9CI) (CA INDEX NAME)



● HCl

RN 879499-80-6 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-, monohydrochloride, (1E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 879499-84-0 CAPLUS
CN 2-Thiopheneethanesulfonamide, 5-chloro-N-[(3S)-1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879499-85-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2,3-dihydro-1-(methylamino)-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879499-86-2 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2,3-dihydro-1-(methylamino)-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry as shown.



RN 879499-87-3 CAPLUS
CN 2-Thiopheneethanesulfonamide, 5-chloro-N-[(3S)-1-[2,3-dihydro-1-(methylamino)-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879499-88-4 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-1-[2,3-dihydro-1-(methylamino)-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879499-89-5 CAPLUS
CN 2-Naphthalenesulfonamide, N-[(3S)-1-(1-amino-2,3-dihydro-1H-inden-5-yl)-2-

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 879500-20-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[(1S)-1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 879500-19-3
CMF C25 H26 Cl N3 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 879500-21-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



Karen Cheng

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879499-90-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2,3-dihydro-1-(methylamino)-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879500-18-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[(1R)-1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 879500-17-1
CMF C25 H26 Cl N3 O3 S

Absolute stereochemistry.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 879500-22-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



IT 879500-01-3P 879500-05-7P 879500-06-8P
879500-07-9P 879500-08-0P 879500-09-1P
879500-13-7P 879500-14-8P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of N-[1-(2,3-dihydro-1H-inden-5-yl)-2-oxo-3-pyrrolidinyl] sulfonamides as Factor Xa inhibitors)
RN 879500-01-3 CAPLUS
CN 1H-Indole-6-sulfonamide, 3-chloro-N-[(3S)-1-[1-(dimethylamino)-2,3-dihydro-1H-inden-5-yl]-2-oxo-3-pyrrolidinyl]-1-[tris(1-methylethyl)silyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879500-05-7 CAPLUS
CN Acetamide, N-[5-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 879500-06-8 CAPLUS
CN Acetamide, N-[5-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 879500-07-9 CAPLUS
CN Acetamide, N-[5-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879500-08-0 CAPLUS
CN Acetamide, N-[5-[(3S)-3-[[[3-chloro-1-[tris(1-methylethyl)silyl]-1H-indol-6-yl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 879500-09-1 CAPLUS
CN Acetamide, N-[5-[(3S)-3-[[(3-chloro-1H-indol-6-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879500-13-7 CAPLUS

L3 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Acetamide, N-[5-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 879500-14-8 CAPLUS
CN Acetamide, N-[5-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-2,3-dihydro-1H-inden-1-yl]-2,2,2-trifluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:394818 CAPLUS
DOCUMENT NUMBER: 142:447111
TITLE: Preparation of sulfonylaminovalerolactams and derivatives thereof as factor Xa inhibitors
INVENTOR(S): Han, Wei; Hu, Zilun; Gungor, Timur
PATENT ASSIGNEE(S): USA
SOURCE: U.S. Pat. Appl. Publ., 120 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2005096309	A1	20050505	US 2004-952396	20040928
WO 2005048922	A2	20050602	WO 2004-US31774	20040929
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1667635	A2	20060614	EP 2004-817779	20040929
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, HR				

PRIORITY APPLN. INFO.: US 2003-507177P P 20030930
US 2004-952396 A 20040928
WO 2004-US31774 W 20040929

OTHER SOURCE(S): MARPAT 142:447111
GI

L3 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



AB The present application describes sulfonylaminovalerolactams and derivs. thereof of formula I-VI or pharmaceutically acceptable salt forms thereof [wherein the central lactam ring is optionally substituted; ring G = (un)substituted mono- or bicyclic carbocycle or heterocycle; X = SO2, (un)substituted NH; G1 = H, cyano, each (un)substituted (CH2)1-2-C(O)H, NH2, (CH2)2-5-NH2, (CH2)2-5-OH, C1-6 alkyl, etc.; G2 = (un)substituted CH2CH2 or CH:CH; A = each (un)substituted C3-10 cycloalkyl, C3-10 cycloalkenyl, or 4- to 12-membered heterocyclyl; B = cyano, (un)substituted C1-6 alkyl, C2-6 alkenyl, C2-6 alkynyl, C1-6 alkoxy, etc.]. These compds. are useful as inhibitors of trypsin-like serine proteases, specifically factor Xa, for treating thromboembolic disorders which is selected from arterial or venous cardiovascular thromboembolic disorders. Thus, reductive amination of cyclopentanone by (S)-6-chloronaphthalene-2-sulfonic acid N-(2-oxo-[1,4']bipiperidinyl-3-yl)amide and sodium cyanoborohydride in THF at room temperature for 5 h gave (S)-6-chloronaphthalene-2-sulfonic acid N-(1'-cyclopentyl-2-oxo-[1,4']bipiperidinyl-3-yl)amide. The compds. I inhibited factor Xa with Ki of ≤10 μM. Some of the compds. I also inhibited human thrombin with ki of ≤10 μM.

IT 851120-39-3P, (S)-N-[4-[3-[[(2-Chloronaphthalen-6-yl)sulfonyl]amino]-2-oxopyrrolidin-1-yl]phenyl]-2-(dimethylamino)-N-methylacetamide 851223-86-4P, (S)-6-Chloronaphthalene-2-sulfonic Acid N-[1-(4-isopropylcyclohexyl)-2-oxopyrrolidin-3-yl]amide 851223-87-5P, (S)-[4-[3-[[(6-Chloronaphthalen-2-yl)sulfonyl]amino]-2-oxopyrrolidin-1-yl]cyclohexyl]carbamic acid tert-butyl ester 851223-88-6P, (S)-6-Chloronaphthalene-2-sulfonic acid N-[1-(4-diethylaminocyclohexyl)-2-oxopyrrolidin-3-yl]amide

L3 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 851223-88-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(diethylamino)cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851223-89-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[trans-4-(methylamino)cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
851223-89-7P, (S)-6-Chloronaphthalene-2-sulfonic acid N-[trans-1-(4-methylaminocyclohexyl)-2-oxopyrrolidin-3-yl]amide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sulfonylaminovalerolactams and derivs. thereof as factor Xa inhibitors for treating thromboembolic disorders)

RN 851120-39-3 CAPLUS
CN Acetamide, N-[4-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]phenyl]-2-(dimethylamino)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851223-86-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(1-methylethyl)cyclohexyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 851223-87-5 CAPLUS
CN Carbamic acid, [4-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]cyclohexyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2005:57643 CAPLUS
DOCUMENT NUMBER: 142:159496
TITLE: Semiconductor for photoelectric conversion material, photoelectric converter, and photoelectrochemical cell
INVENTOR(S): Otsu, Shinya; Ofuku, Koji; Kagawa, Nobuaki
PATENT ASSIGNEE(S): Konica Minolta Holdings, Inc., Japan
SOURCE: Jpn. Kokai Tokkyo Koho, 31 pp.
CODEN: JKXXAF
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
JP 2005019124	A	20050120	JP 2003-180739	20030625
PRIORITY APPLN. INFO.:			JP 2003-180739	20030625

OTHER SOURCE(S): MARPAT 142:159496
GI



AB The semiconductor contains a heterocyclic compound I (R1, R2, R3 = H or substituent; R1 and R2, R2 and R3 may form a ring; R4 = H, carboxyl, or -L-(CO2H)m group; L = bivalent linking group; m = 0 or 1; J1 = aliphatic, aromatic, or heterocyclic group; X = O or S; Z1 = aromatic C or heterocyclic ring; and n = 0 or 1) or II (R1', R2', R3' = H or substituent; R1' and R2', R2' and R3' may form a ring; X = O or S; Z1, Z2 = residue group necessary for forming aromatic C or heterocyclic ring; and n', m' = 0 or 1).
The photoelec. converter has a layer of the above semiconductor on a conductive support. The photoelectrochem. cell has the above photoelec. converter, a charge transporting layer, and a counter electrode.

IT 827609-72-3
RL: MOA (Modifier or additive use); USES (Uses)
(semiconductors containing heterocyclic compds. for photoelec. converters in photoelectrochem. cells)

RN 827609-72-3 CAPLUS

L3 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzoic acid, 4-[3-[5-(dimethylamino)-2-thienyl]-2,5-dihydro-2,5-dioxo-4-[(phenylsulfonyl)amino]-1H-pyrrol-1-yl]- (9CI) (CA INDEX NAME)



L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1127376 CAPLUS
DOCUMENT NUMBER: 142:74569
TITLE: Preparation of 3-sulfonylamino-pyrrolidine-2-one derivatives as factor Xa inhibitors
INVENTOR(S): Borthwick, Alan David; Kelly, Henry Anderson; Watson, Nigel Stephen; Young, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 43 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004111045	A1	20041223	WO 2004-EP6603	20040617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1641786	A1	20060405	EP 2004-740049	20040617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006527731	T	20061207	JP 2006-515993	20040617
US 2006167079	A1	20060727	US 2005-561414	20051219
PRIORITY APPLN. INFO.:			GB 2003-14373	A 20030619
			WO 2004-EP6603	W 20040617

OTHER SOURCE(S): MARPAT 142:74569
GI

look for ODP

L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I II

AB Title compds. represented by the formula I [wherein R1 = (un)substituted naphthyl, benzofuryl, phenyl(alkyl), etc.; R2 = H, alkyl, alkylamido, carbonylalkyl, etc.; X = (un)substituted Ph or aromatic heterocyclic group; Y = (un)substituted Ph or aromatic heterocyclic group; and pharmaceutically acceptable derivs. thereof] were prepared as inhibitors of factor Xa. For example, II was given in a multi-step synthesis starting from the reaction of 2-fluoro-4-iodoaniline with tert-Bu ((3S)-tetrahydro-2-oxo-3-furanyl)carbamate. The prepared compds. showed activity in vitro assay for inhibition of factor Xa with Ki values of less than 100 nM. Thus, I and their pharmaceutical compns. are useful medicine, particularly in the amelioration of a clin. condition for which a factor Xa inhibitor is indicated (no data).
IT 811794-78-2P 811794-79-3P 811794-80-6P
811794-81-7P 811794-82-8P 811794-83-9P
811794-84-0P 811794-85-1P 811794-86-2P
811794-87-3P 811794-88-4P 811794-89-5P
811794-90-8P 811794-91-9P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-(imidazolyl)phenyl-3-(sulfonylamino)pyrrolidin-2-one derivs. as factor Xa inhibitors)
RN 811794-78-2 CAPLUS
CN 1-Propene-1-sulfonamide, N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-79-3 CAPLUS
CN Formic acid, compd. with (1E)-N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-1-propene-1-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-78-2
CMF C24 H25 Cl F N5 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-80-6 CAPLUS
CN 2-Thiopheneethanesulfonamide, N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-5-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-81-7 CAPLUS
CN Formic acid, compd. with N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-5-chloro-2-thiopheneethanesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-80-6
CMF C23 H25 Cl F N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-82-8 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-83-9 CAPLUS
CN Formic acid, compd. with N-[(3S)-1-[4-[2-(1-azetidinylmethyl)-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chlorobenzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-82-8
CMF C25 H23 Cl F N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-84-0 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-85-1 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-84-0
CMF C24 H24 Cl F2 N5 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-86-2 CAPLUS
CN 1-Propene-1-sulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-87-3 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-86-2
CMF C25 H26 Cl F2 N5 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-88-4 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-89-5 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[2-fluoro-4-[2-[(3-fluoro-1-pyrrolidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-88-4
CMF C26 H24 Cl F2 N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 811794-90-8 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-[2-[(3-methoxy-1-azetidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-91-9 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[2-fluoro-4-[2-[(3-methoxy-1-azetidinyl)methyl]-1H-imidazol-1-yl]phenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-90-8
CMF C26 H25 Cl F N5 O4 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:1127332 CAPLUS
DOCUMENT NUMBER: 142:74444
TITLE: Preparation of 3-sulfonylamino-pyrrolidine-2-one derivatives as factor Xa inhibitors
INVENTOR(S): Borthwick, Alan David; Harling, John David; Irving, Wendy Rebecca; Kleanthous, Savvas; Watson, Nigel Stephen; Young, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 101 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110997	A1	20041223	WO 2004-EP6604	20040617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1641752	A1	20060405	EP 2004-740050	20040617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006527732	T	20061207	JP 2006-515994	20040617
US 2006178419	A1	20060810	US 2005-561328	20051219
PRIORITY APPLN. INFO.:			GB 2003-14369 A	20030619
			GB 2004-5774 A	20040315
			WO 2004-EP6604 W	20040617

OTHER SOURCE(S): MARPAT 142:74444
GI

current app

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I II

AB Title compds. represented by the formula I [wherein R1 = (un)substituted naphthyl, benzofuryl, phenyl(alkyl), etc.; R2 = H, alkyl, alkylamido, carbonylalkyl, etc.; X = (un)substituted Ph or aromatic heterocyclic group; Y = (halo)alkylamino; and pharmaceutically acceptable derivs. thereof] were prepared as inhibitors of factor Xa. For example, II was given in a multi-step synthesis starting from the reaction of 2-fluoro-4-iodoaniline with tert-Bu [(3S)-2-oxotetrahydro-3-furanyl]carbamate. The prepared compds. showed activity in vitro assay for inhibition of factor Xa and in measurement of prothrombin time (PT) of human plasma. Thus, I and their pharmaceutical compns. are useful medicine, particularly in the amelioration of a clin. condition for which a factor Xa inhibitor is indicated (no data).

IT 811799-98-1P 811799-99-2P 811800-00-7P
811800-01-8P 811800-03-0P 811800-04-1P
811800-05-2P 811800-06-3P 811800-07-4P
811800-08-5P 811800-09-6P 811800-10-9P
811800-11-0P 811800-12-1P 811800-13-2P
811800-14-3P 811800-15-4P 811800-16-5P
811800-18-7P 811800-20-1P 811800-22-3P
811800-23-4P 811800-24-5P 811800-25-6P
811800-27-8P 811800-28-9P 811800-29-0P
811800-30-3P 811800-31-4P 811800-32-5P
811800-33-6P 811800-34-7P 811800-35-8P
811800-36-9P 811800-37-0P 811800-38-1P
811800-39-2P 811800-40-5P 811800-41-6P
811800-42-7P 811800-43-8P 811800-44-9P
811800-45-0P 811800-46-1P 811800-47-2P
811800-48-3P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(sulfonylamino)pyrrolidine-2-one derivs. as inhibitors of factor Xa)

RN 811799-98-1 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811799-99-2 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811799-98-1
CMF C20 H23 Cl F N3 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-00-7 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[1-(4-morpholinyl)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-04-1 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[4-[1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-05-2 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



Karen Cheng

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811800-01-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[1-[(2-hydroxyethyl)methylamino]ethyl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-03-0 CAPLUS
CN Formic acid, compd. with (1E)-N-[(3S)-1-[4-(1-aminoethyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-02-9
CMF C18 H19 Cl F N3 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 811800-06-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-07-4 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-08-5 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-09-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.



RN 811800-10-9 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-11-0 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]-2,6-difluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-12-1 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]-2,6-difluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)-(9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-15-4 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)-2-methylpropyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-16-5 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)-2-methylpropyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-15-4
CMF C22 H27 Cl F N3 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-13-2 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)propyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)-(9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-14-3 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)propyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-13-2
CMF C21 H25 Cl F N3 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-18-7 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(dimethylamino)-1-methylethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-17-6
CMF C21 H25 Cl F N3 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-20-1 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[4-[1-(dimethylamino)-1-methylethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
naphthalenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-19-8
CMF C25 H27 Cl F N3 O3 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-22-3 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[4-[1-(dimethylamino)-1-methylethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-21-2
CMF C23 H25 Cl F N3 O3 S2

Absolute stereochemistry.



CM 2

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 64-18-6
CMF C H2 O2



RN 811800-23-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[4-[1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-24-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[4-[1-(ethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-25-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[4-[1-(ethylmethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 811800-27-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[2-fluoro-4-[1-(methyl(1-methylethyl)amino]ethyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-28-9 CAPLUS
CN 2-Naphthalenesulfonamide,
N-[1-[4-[1-(1-azetidinyl)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)



RN 811800-29-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[2-fluoro-4-[1-(1-pyrrolidinyl)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-30-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[2-fluoro-4-[1-(1-piperidinyl)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811800-31-4 CAPLUS
CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-1-[4-[1-(dimethylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-32-5 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-33-6 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-32-5
CMF C20 H24 Cl N3 O3 S2

Absolute stereochemistry.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2



RN 811800-34-7 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811800-35-8 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]ethenesulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-34-7
CMF C20 H24 Cl N3 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-38-1 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-39-2 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[4-[(1R)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-38-1
CMF C22 H24 Cl N3 O3 S2

Absolute stereochemistry.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-36-9 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811800-37-0 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[4-[(1S)-1-(dimethylamino)ethyl]phenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-36-9
CMF C22 H24 Cl N3 O3 S2

Absolute stereochemistry.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-40-5 CAPLUS
CN 1-Propene-1-sulfonamide, 2-(5-chloro-2-thienyl)-N-[1-[4-[1-(dimethylamino)ethyl]-2,6-difluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 811800-41-6 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[1-[4-[1-(dimethylamino)ethyl]-2,6-difluorophenyl]-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811800-40-5
CMF C21 H24 Cl F2 N3 O3 S2

Double bond geometry as shown.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-42-7 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[1-[4-[1-(dimethylamino)ethyl]-2,6-difluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-43-8 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[1-[4-[1-(dimethylamino)ethyl]-2,6-difluorophenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 811800-42-7
CMF C22 H22 Cl F2 N3 O3 S2

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811800-44-9 CAPLUS
CN Ethenesulfonamide, N-[1-[4-(1-aminoethyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 811800-45-0 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[1-[4-[1-(dimethylamino)-1-methylethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 811800-46-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[4-[1-(dimethylamino)-1-methylethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-47-2 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[1-[4-[1-(dimethylamino)-1-methylethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811800-48-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[2-fluoro-4-[1-[(1-methylethyl)amino]ethyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



IT 553651-70-0P 553651-94-8P 553653-26-2P
553653-27-3P 811799-51-6P 811799-52-7P
811799-53-8P 811799-81-2P 811799-82-3P
811799-83-4P 811799-84-5P 811799-86-7P
811799-87-8P 811800-26-7P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(sulfonylamino)pyrrolidine-2-one derivs. as inhibitors of
factor Xa)

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 553651-70-0 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-(4-acetyl-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-94-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-(1-hydroxyethyl)phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553653-26-2 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-[4-(1-bromoethyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553653-27-3 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(diformylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811799-51-6 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, N-[(3S)-1-(4-acetyl-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811799-52-7 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-hydroxyethyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811799-53-8 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, N-[(3S)-1-[4-(1-bromoethyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811799-84-5 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811799-86-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[1-[2-fluoro-4-(1-hydroxyethyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 811799-87-8 CAPLUS
CN 2-Naphthalenesulfonamide, N-[1-[4-(1-bromoethyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)



Karen Cheng

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811799-81-2 CAPLUS
CN 2-Naphthalenesulfonamide, N-[(3S)-1-(4-acetyl-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811799-82-3 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811799-83-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-hydroxy-1-methylethyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

RN 811800-26-7 CAPLUS
CN 2-Naphthalenesulfonamide, N-[1-(4-acetyl-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE

FORMAT

L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1124629 CAPLUS
DOCUMENT NUMBER: 142:74440
TITLE: Preparation of 3-(sulfonylamino)pyrrolidin-2-one derivatives as factor Xa inhibitors
INVENTOR(S): Borthwick, Alan David; Chan, Chuen; Kelly, Henry Anderson; Kleanthous, Savvas; Mason, Andrew Mcmurtrie; Watson, Nigel Stephen
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 50 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110435	A1	20041223	WO 2004-EP6592	20040617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1635817	A1	20060322	EP 2004-736979	20040617
EP 1635817	B1	20061122		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006527729	T	20061207	JP 2006-515988	20040617
AT 345795	T	20061215	AT 2004-736979	20040617
US 2006148879	A1	20060706	US 2005-561545	20051219
PRIORITY APPLN. INFO.:			GB 2003-14299 A	20030619
			WO 2004-EP6592 W	20040617

OTHER SOURCE(S): MARPAT 142:74440
GI

ODP?
NO

L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I II

AB Title compds. represented by the formula I [wherein R1 = (un)substituted naphthyl, 2-benzofuryl, phenyl(alkyl), etc.; R2 = alkyl(cycloalkyl), alkylamino, alkoxyalkyl, etc.; with the proviso that R2 does not present alkylmorpholino; X = (un)substituted Ph or aromatic heterocyclic group; Y = H, halo, alkyl, amino, etc.; and pharmaceutically acceptable derivs. thereof] were prepared as inhibitors of factor Xa. For example, II was given in a multi-step synthesis starting from the reaction of 2-fluoro-4-iodoaniline with tert-Bu ((3S)-2-oxotetrahydro-3-furanyl)carbamate. The prepared compds. showed activity in vitro assay for inhibition of factor Xa with Ki values less than 0.1 μM, and in measurement of prothrombin time (PT) of human plasma. Thus, I and their pharmaceutical compns. are useful medicine, particularly in the amelioration of a clin. condition for which a factor Xa inhibitor is indicated (no data).

IT 811788-71-3P 811788-72-4P 811788-73-5P
811788-74-6P 811788-75-7P 811788-76-8P
811788-77-9P 811788-78-0P 811788-79-1P
811788-80-4P 811788-81-5P 811788-82-6P
811788-83-7P 811788-84-8P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 3-(sulfonylamino)pyrrolidine-2-one derivs. as factor Xa inhibitors)

RN 811788-71-3 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl](cyclopropylmethyl)amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811788-72-4 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl][3-(dimethylamino)propyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-73-5 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl][2-(dimethylamino)ethyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-74-6 CAPLUS
CN Benzamide, 4-[(3S)-3-[[2-(2-amino-2-oxoethoxy)ethyl][[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811788-75-7 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]cyclopentylamino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-76-8 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl][(1-methyl-1H-imidazol-2-yl)methyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-77-9 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl](1-methylethyl)amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-78-0 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl](2-pyridinylmethyl)amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-79-1 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl][(3,5-dimethyl-4-isoxazolyl)methyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 811788-82-6 CAPLUS
CN Benzamide, 4-[(3S)-3-[[(3-aminopyrazinyl)methyl][[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-83-7 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-84-8 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]methylamino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811788-80-4 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl](2-methoxyethyl)amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811788-81-5 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl][2-(1,1-dimethylethoxy)ethyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 553651-62-0P 553651-68-6P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 3-(sulfonylamino)pyrrolidine-2-one derivs. as factor Xa inhibitors)
RN 553651-62-0 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-68-6 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

Karen Cheng

L3 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:1124628 CAPLUS
DOCUMENT NUMBER: 142:74439
TITLE: Preparation of 3-(sulfonylamino)pyrrolidine-2-one derivatives as factor Xa inhibitors
INVENTOR(S): Borthwick, Alan David; Kleanthous, Savvas; Senger, Stefan; Smith, Ian Edward David
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 60 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004110434	A1	20041223	WO 2004-EP6591	20040617
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1633347	A1	20060315	EP 2004-740039	20040617
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK, HR				
JP 2006527728	T	20061207	JP 2006-515987	20040617
PRIORITY APPLN. INFO.:			GB 2003-14370	A 20030619
			WO 2004-EP6591	W 20040617

OTHER SOURCE(S): MARPAT 142:74439
GI

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

II

AB Title compds. represented by the formula I [wherein R1 = (un)substituted naphthyl, 2-benzofuryl, thienylalkyl, phenyl(alkyl), etc.; R2 = H, alkyl, alkylamido, carbonylalkoxy, etc.; X = (un)substituted Ph or aromatic heterocyclic group; Y = absent or alkylene; and pharmaceutically acceptable derivs. thereof] were prepared as inhibitors of factor Xa. For example, II was given in a multi-step synthesis starting from the reaction of 2-fluoro-4-iodoaniline with tert-Bu ((3S)-2-oxotetrahydro-3-furanyl)carbamate. Most of the prepared compds. showed activity in vitro assay for inhibition of factor Xa with Ki values of less than 1 μM. Thus, I and their pharmaceutical compns. are useful medicine, particularly in the amelioration of a clin. condition for which a factor Xa inhibitor is indicated (no data).

IT 811793-44-9P 811793-49-4P 811793-53-0P 811793-56-3P 811793-61-0P 811793-62-1P 811793-65-4P 811793-69-8P 811793-71-2P 811793-74-5P 811793-76-7P 811793-79-0P 811793-82-5P 811793-83-6P 811793-84-7P 811793-86-9P 811793-87-0P 811793-90-5P 811793-92-7P 811793-94-9P 811793-96-1P 811793-98-3P 811793-99-4P 811794-01-1P 811794-02-2P 811794-03-3P 811794-04-4P 811794-05-5P 811794-07-7P 811794-09-9P 811794-11-3P 811794-12-4P 811794-14-6P 811794-16-8P 811794-18-0P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of 1-phenyl-3-(sulfonylamino)pyrrolidine-2-one derivs. as factor Xa inhibitors)

RN 811793-44-9 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



not in claims.

RN 811793-49-4 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(2-hydroxyethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-53-0 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-(2-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-56-3 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylsulfonyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

Karen Cheng

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811793-61-0 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-62-1 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-65-4 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-(2-phenylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-69-8 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-71-2 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(3-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811793-74-5 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(2-hydroxyethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-76-7 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(phenylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-79-0 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(2-methoxyethyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811793-82-5 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-83-6 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylsulfonyl)ethyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-84-7 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-2-propenyl- (9CI) (CA INDEX NAME)

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-86-9 CAPLUS
CN Benzamide, N-(2-amino-2-oxoethyl)-4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-87-0 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-(4-pyridinylmethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-90-5 CAPLUS

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811793-96-1 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[3-(methylamino)-3-oxopropyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-98-3 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(5-methyl-1H-imidazol-4-yl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-99-4 CAPLUS
CN Glycine,
N-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorobenzoyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(1-pyrrolidinyl)ethyl]- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-92-7 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-[2-(1H-imidazol-4-yl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811793-94-9 CAPLUS
CN Benzamide,
4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-(3-hydroxypropyl)-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry as shown.



RN 811794-01-1 CAPLUS
CN Glycine,
N-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorobenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-02-2 CAPLUS
CN Benzamide,
4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-03-3 CAPLUS
CN Formic acid, compd. with 4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-N-methylbenzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-02-2

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CMF C24 H26 Cl F N4 O4 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811794-04-4 CAPLUS
CN Benzamide,
4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-05-5 CAPLUS
CN Formic acid, compd. with 4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylamino)ethyl]benzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-04-4
CMF C23 H24 Cl F N4 O4 S2

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 811794-11-3 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-12-4 CAPLUS
CN Formic acid, compd. with 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-N-[2-(dimethylamino)ethyl]-3-fluoro-N-methylbenzamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 811794-11-3
CMF C23 H28 Cl F N4 O4 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 811794-07-7 CAPLUS
CN Benzamide,
4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-09-9 CAPLUS
CN Benzamide, N-(2-aminoethyl)-4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 64-18-6
CMF C H2 O2

RN 811794-14-6 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(3-pyridinyl)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-16-8 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-[2-(1H-imidazol-4-yl)ethyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-18-0 CAPLUS
CN Benzamide, 4-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-[2-(methylamino)ethyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



IT 811794-25-9P 811794-28-2P 811794-29-3P
811794-30-6P 811794-31-7P 811794-36-2P
811794-38-4P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of 1-phenyl-3-(sulfonylamino)pyrrolidine-2-one derivs. as factor Xa inhibitors)

RN 811794-25-9 CAPLUS
CN Benzoic acid, 4-[[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-28-2 CAPLUS
CN Benzoic acid, 4-[[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.



RN 811794-38-4 CAPLUS
CN Benzoic acid, 4-[[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



REFERENCE COUNT: 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 811794-29-3 CAPLUS
CN Benzoic acid, 4-[[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 811794-30-6 CAPLUS
CN Benzoic acid, 4-[[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-, phenylmethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-31-7 CAPLUS
CN Benzoic acid, 4-[[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 811794-36-2 CAPLUS
CN Benzoic acid, 4-[[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-, phenylmethyl ester (9CI) (CA INDEX NAME)

L3 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:701975 CAPLUS
DOCUMENT NUMBER: 141:225304
TITLE: Preparation of cyclohexyl-substituted lactams as cytokine receptor modulating agents
INVENTOR(S): Cherney, Robert J.; Carter, Percy; Duncia, John V.; Gardner, Daniel S.; Santella, Joseph B.
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: PCT Int. Appl., 385 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004071460	A2	20040826	WO 2004-US4418	20040211
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI				
RW: BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
US 2004186140	A1	20040923	US 2004-776828	20040211
EP 1606255	A2	20051221	EP 2004-710294	20040211
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				

PRIORITY APPLN. INFO.: US 2003-446850P P 20030212
WO 2004-US4418 W 20040211

OTHER SOURCE(S): MARPAT 141:225304
GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Cyclohexyl-substituted lactams I [A = (un)substituted saturated or partially saturated cycloalkyl or heterocycloalkyl group with 3-8 atoms; E = S(:O)pCHR3, CHR3NR3, C(:O)NR3, N(R3)C(:O)NR3, SO2N(R3), N(R3)SO2N(R3); G = (CHR10)n; J = CH2CH2, CH:CH un(substituted) with (R13)s; R1, R2 = (un)substituted aryl or heteroaryl ring; R3 = H, alkyl; R10 = H, (un)substituted alkyl (two R10 groups may together comprise a carbonyl group); R11, R12 (independently) = H, (un)substituted alkyl, aralkyl, heteroaralkyl, ω-hydroxyalkyl, ω-mercaptoalkyl, ω-alkoxyalkyl, etc.; R13 = H, (un)substituted alkyl; X = O, S; Z = bond, (un)substituted aminocarbonyl, aminothiocarbonyl, aminocarbonylamino, aminothiocarbonylamino, aminosulfonyl, aminosulfonylamino, carbonylamino, oxycarbonylamino, aminocarbonyloxy, alkenediyl, methylene, etc.; m = 0-1; n = 0-3; s = 0-1]

L3 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

such as II are prepd. as modulators of cytokine activity for the treatment of diseases assocd. with cytokines and their receptors such as inflammation, osteo- and rheumatoid arthritis, autoimmune diseases, HIV infection, inflammatory bowel disease, asthma, multiple sclerosis, and atherosclerosis. E.g., 1,4-cyclohexanedione mono(ethylene ketal) is lithiated and acylated with Et cyanoformate, reductively aminated with (S)-α-methylbenzylamine, subjected to redn. with lithium aluminum hydride followed by hydrogenolysis with palladium hydroxide and protection with Cbz anhydride to yield nonracemic III. E.g., III undergoes substitution at the primary carbon with 4-bromophenyl disulfide and tributylphosphine followed by oxidn. with mCPBA, Stille methylation of the p-bromophenyl moiety, hydrogenolysis of the Cbz protecting group, acylation with N-Cbz-L-methionine, and S-methylation and cyclization with Me iodide and cesium carbonate to yield IV. E.g., IV undergoes acid-catalyzed deketalization, titanium-mediated Meerwein-Pondorff-Verley redn. with isopropylamine (giving a mixt. of both epimers at the amine center), N-methylation with formaldehyde and sodium triacetoxyborohydride, hydrogenolysis of the Cbz protecting group on the aminopyrrolidinone, and acylation with 3-trifluoromethylbenzoic acid and HATU to yield II. The compds. are modulators of chemokine receptor activity (no data). In addn., methods of halolactamization and dehalogenation and reagents appropriate for such transformations are claimed.

IT 746666-97-7P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of cyclohexyl-substituted lactams as modulators for cytokine receptor activity in the treatment of conditions such as inflammation, rheumatoid arthritis, asthma, multiple sclerosis, and atherosclerosis)

RN 746666-97-7 CAPLUS

CN Benzenesulfonamide, N-[(3S)-1-[(1S,2R,4R)-4-[methyl(1-methylethyl)amino]-2-[[[4-(methylthio)phenyl]sulfonyl]methyl]cyclohexyl]-2-oxo-3-pyrrolidinyl]-3-(trifluoromethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 2004:267295 CAPLUS
DOCUMENT NUMBER: 140:287260
TITLE: Preparation of 4-pyrrolidinophenyl benzyl ether derivatives as monoamine oxidase B inhibitors
INVENTOR(S): Jolidon, Synese; Rodriguez-Sarmiento, Rosa Maria; Thomas, Andrew William; Wostl, Wolfgang; Wyler, Rene
PATENT ASSIGNEE(S): F. Hoffmann-La Roche A.-G., Switz.
SOURCE: PCT Int. Appl., 37 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 3
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2004026826	A1	20040401	WO 2003-EP10383	20030918
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2498335	A1	20040401	CA 2003-2498335	20030918
AU 2003273901	A1	20040408	AU 2003-273901	20030918
US 2004097578	A1	20040520	US 2003-666594	20030918
US 2004106650	A1	20040603	US 2003-667088	20030918
US 7037935	B2	20060502		
US 2004116707	A1	20040617	US 2003-667087	20030918
US 7151111	B2	20061219		
EP 1542971	A1	20050622	EP 2003-757866	20030918
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
BR 2003014314	A	20050726	BR 2003-14314	20030918
CN 1681777	A	20051012	CN 2003-821256	20030918
CN 1681778	A	20051012	CN 2003-821767	20030918
CN 1681779	A	20051012	CN 2003-821952	20030918
JP 2006503834	T	20060202	JP 2004-537120	20030918
NO 2005000701	A	20050302	NO 2005-701	20050209
ZA 2005001557	A	20050908	ZA 2005-1557	20050222
US 2006122235	A1	20060608	US 2006-325747	20060105
US 7122562	B2	20061017		
PRIORITY APPLN. INFO.:			EP 2002-21319 A	20020920
			US 2003-667088 A3	20030918
			WO 2003-EP10383 W	20030918

OTHER SOURCE(S): MARPAT 140:287260
GI

L3 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I

AB Title compds. I [R = (un)substituted Ph; X-Y = CH2CH2, CH:CH, CH2O; R1-R3 = H, halogen; R4 = H, halogen, Me; R5 = (un)substituted CONH2, NH2] were prepared for use in the prevention and treatment of illness mediated by monoamine oxidase B, in particular Alzheimer's disease or senile dementia (no data). Thus, 4-PhCH2OC6H4NH2 was treated with BrCH2CH2CHBrCOCl and the resulting amide cyclized with Dowex 2X10 to give 1-(4-benzyloxyphenyl)-3-bromo-2-pyrrolidinone which was treated with NaCN to give the 3-cyano analog.

IT 676232-70-5P 676232-73-8P 676232-74-9P

RL: SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)

(preparation of 4-pyrrolidinophenyl benzyl ether derivs. as monoamine oxidase B inhibitors)

RN 676232-70-5 CAPLUS

CN Methanesulfonamide, N-[(3S)-2-oxo-1-[4-(phenylmethoxy)phenyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 676232-73-8 CAPLUS

CN Methanesulfonamide, N-[(3R)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 676232-74-9 CAPLUS
CN Methanesulfonamide, N-[(3S)-1-[4-[(3-fluorophenyl)methoxy]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2004:20333 CAPLUS
DOCUMENT NUMBER: 140:93926
TITLE: Preparation of sulfonylaminovalerolactams as factor Xa inhibitors
INVENTOR(S): Smallheer, Joanne M.; Pinto, Donald J.; Wang, Shuaige; Qiao, Jennifer X.; Han, Wei; Hu, Zilun
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company, USA
SOURCE: U.S. Pat. Appl. Publ., 89 pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 2004006062	A1	20040108	US 2003-429461	20030505
US 7157470	B2	20070102		
WO 2004041776	A2	20040521	WO 2003-US14142	20030505
WO 2004041776	A3	20040910		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2003301863	A1	20040607	AU 2003-301863	20030505
EP 1501798	A2	20050202	EP 2003-808359	20030505
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
US 2006247243	A1	20061102	US 2006-472825	20060621

PRIORITY APPLN. INFO.: US 2002-378313P P 20020506
US 2003-429461 A3 20030505
WO 2003-US14142 W 20030505

OTHER SOURCE(S): MARPAT 140:93926
GI

L3 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I



II

AB The title compds. I [G = Ph, pyridyl, pyrrolyl, etc.; G1 = H, alkyl, acyl, (substituted) amino, etc.; A = (substituted) Ph, carbocyclic, heterocyclyl; B = lactam, heterocyclyl, etc.; n = 0-2] were prepared I can be used as inhibitors of trypsin-like serine proteases, specifically factor Xa. Thus, II is prepared from 1-[4-(3-amino-2-oxopiperidin-1-yl)-3-fluorophenyl]-piperidin-2-one (preparation given) and 6-chloronaphthalene-2-sulfonyl chloride. Pharmaceutical compds. containing I are described.

IT 641612-43-3P 641612-44-4P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of sulfonylaminovalerolactams as factor Xa inhibitors)

RN 641612-43-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[2-oxo-1-[4-(2-oxo-1-piperidinyl)phenyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



RN 641612-44-4 CAPLUS

Karen Cheng

L3 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN 2-Naphthalenesulfonamide, 6-chloro-N-[2-oxo-1-[4-(2-oxo-1(2H)-pyridinyl)phenyl]-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)



REFERENCE COUNT: 19 THERE ARE 19 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:777806 CAPLUS
DOCUMENT NUMBER: 139:292253
TITLE: Preparation of novel dithiolopyrrolones with therapeutic activity against proliferative diseases
INVENTOR(S): Chen, Genhui; Li, Bin; Li, Jianxiong; Webster, John
PATENT ASSIGNEE(S): Welichem Biotech Inc., Can.
SOURCE: PCT Int. Appl., 33 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003080624	A2	20031002	WO 2003-CA380	20030318
WO 2003080624	A3	20040325		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2479341	A1	20031002	CA 2003-2479341	20030318
AU 2003209899	A1	20031008	AU 2003-209899	20030318
EP 1490374	A2	20041229	EP 2003-744744	20030318
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
CN 1642959	A	20050720	CN 2003-806882	20030318
JP 2005526803	T	20050908	JP 2003-578378	20030318
US 2006074125	A1	20060406	US 2005-509074	20051014
PRIORITY APPLN. INFO.:			US 2002-367265P	P 20020326
			US 2002-418698P	P 20021017
			WO 2003-CA380	W 20030318

OTHER SOURCE(S): MARPAT 139:292253
GI

L3 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



I II

AB The present invention provides novel dithiolopyrrolone compds. (I) [X and Y can be the same or different, are hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, aralkyl or heterocyclic group except the compds. with: Z = Ph, Y = H, X = H, Me or benzyl, and Z = 4-pyridine, X = Me, Y = H; or When X = aryl, heterocyclic, Y and Z, can be the same or different, are hydrogen, unsubstituted or substituted or alkyl of two or less hydroxy groups and no carboxylic acid group, cycloalkyl, aryl, aralkyl or heterocyclic group, except the compds. with: Z = Me, Y = H, X = Ph, 4-methoxyphenyl, 4-methylphenyl] and their salts, which are useful as treatments for cancer and other proliferative diseases. The present invention also provides therapeutic compns. comprising particularly useful types of dithiolopyrrolones, the salts thereof, and methods of using the compds. within such types, particularly in treating proliferative diseases such as cancer. For example, 1,2-dithiolo[4,3-b]pyrrol-5(4H)-one derivative (II) in vitro showed IC50 of ≤0.01, 0.13, 0.016, 0.14, 0.014, 0.03, 0.04, 0.013, and 0.013 μM against leukemia CCRF-CEM, non-small cell lung cancer, colon cancer HCT-116, CNS cancer 0.14, melanoma LOXIMVI, ovarian cancer OVCAR-3, renal cancer RXF 393, prostate cancer DU-145, and breast cancer T-47D, resp.

IT 608132-34-9P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(preparation of novel dithiolopyrrolones with therapeutic activity against proliferative diseases such as cancer)

RN 608132-34-9 CAPLUS
CN Methanesulfonamide, N-[1-(2,4-dimethoxyphenyl)-4-[(1,1-dimethylethyl)thio]-5-[[(1,1-dimethylethyl)thio]methylene)-2,5-dihydro-2-oxo-1H-pyrrol-3-yl]-N-(methylsulfonyl)- (9CI) (CA INDEX NAME)

L3 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



10561328

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 2003:511293 CAPLUS
DOCUMENT NUMBER: 139:85238
TITLE: Preparation of 3-(sulfonylamino)pyrrolidin-2-ones as factor Xa inhibitors
INVENTOR(S): Borthwick, Alan David; Chan, Chuen; Kelly, Henry Anderson; King, Nigel Paul; Kleanthous, Savvas; Mason, Andrew McMurtrie; Pinto, Ivan Leo; Pollard, Derek Roland; Senger, Stefan; Shah, Gita Punjabhai; Watson, Nigel Stephen; Young, Robert John
PATENT ASSIGNEE(S): Glaxo Group Limited, UK
SOURCE: PCT Int. Appl., 112 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003053925	A1	20030703	WO 2002-EP14826	20021220
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2471461	A1	20030703	CA 2002-2471461	20021220
AU 2002366747	A1	20030709	AU 2002-366747	20021220
EP 1456172	A1	20040915	EP 2002-805350	20021220
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, SK				
BR 2002015200	A	20041013	BR 2002-15200	20021220
CN 1620434	A	20050525	CN 2002-828224	20021220
JP 2005519885	T	20050707	JP 2003-554642	20021220
HU 200500137	A2	20060228	HU 2005-137	20021220
ZA 2004004147	A	20050621	ZA 2004-4147	20040527
NO 2004002990	A	20040920	NO 2004-2990	20040713
US 2005059726	A1	20050317	US 2004-499529	20041101
PRIORITY APPLN. INFO.:			GB 2001-30705 A	20011221
			WO 2002-EP14826 W	20021220

OTHER SOURCE(S): MARPAT 139:85238
GI



AB Title compds. I [wherein R1 = (un)substituted naphthyl, benzothienyl, benzofuryl, indolyl, phenyl(alkyl), 2,2'-bithiophen-5-yl, thienyl(alkyl), or thieno[3,2-b]thiophenyl; R2 = H, (CH2)nCONRaRb, (CH2)nCO2Rc, morpholinoalkyl, CO2Rc, or carboxyalkyl; X = H, halo, CN, alkyl, alkenyl, CF3, NRaRb, NO2, NRcCHO, NHCORc, NHSO2Rc, alkoxyalkyl, hydroxyalkyl, CORc, CONRaRb, SO0-2Rc, SO2NRaRb, or (un)substituted Ph, heterocyclyl, or heteroaryl; n = 1-3; Ra and Rb = independently H or alkyl; or NRaRb = (un)substituted heterocyclyl; Rc = alkyl; and pharmaceutically acceptable derivs. thereof] were prepared as factor Xa inhibitors. For example, coupling of (3S)-3-amino-1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]pyrrolidin-2-one with 6-chloro-2-naphthylsulfonyl chloride in the presence of pyridine in DCM gave II. The latter inhibited human factor Xa in an in vitro fluorogenic assay with Ki <10 nM. Thus, I and compns. comprising I are useful as medicines for the amelioration of clin. conditions for which a Factor Xa inhibitor is indicated (no data).

IT 553650-65-0P 553650-67-2P, (S)-4'-[3-[[[(1E)-2-(5-Chlorothien-2-yl)prop-1-enyl]sulfonyl]amino]-2-oxopyrrolidin-1-yl]-3'-fluoro-1,1'-biphenyl-2-sulfonamide 553650-86-5P, (S)-3-Cyano-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]benzenesulfonamide 553651-02-8P, (S)-6-Chloro-N-[1-(2-fluoro-4-iodophenyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-07-3P, (S)-6-Chloro-N-[1-[2-fluoro-4-(pyridin-4-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-60-8P 553651-65-3P 553651-70-0P, (S)-(E)-N-[1-(4-Acetyl-2-fluorophenyl)-2-oxopyrrolidin-3-yl]-2-(5-chlorothien-2-yl)ethenesulfonamide 553651-94-8P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(factor Xa inhibitor; preparation of (sulfonylamino)pyrrolidinone factor Xa inhibitors starting from homoserines)

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 553650-65-0 CAPLUS
CN Formic acid, compd. with (1E)-2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-1-propene-1-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 553650-64-9
CMF C23 H25 Cl F N5 O3 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH—OH

RN 553650-67-2 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3'-fluoro- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 553650-86-5 CAPLUS
CN Benzenesulfonamide, 3-cyano-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

Karen Cheng

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-02-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(2-fluoro-4-iodophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-07-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 553651-60-8 CAPLUS
CN 2-Naphthalenesulfonamide, N-[(3S)-1-(4-bromo-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-65-3 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-70-0 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-(4-acetyl-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-94-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-(1-hydroxyethyl)phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry as shown.



IT 553650-48-9P, (S)-6-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553650-50-3P, (S)-6-Chloro-N-[1-[4-(dimethylamino)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553650-53-6P, (S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-54-7P, (S)-5-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1-benzofuran-2-sulfonamide 553650-55-8P,

(S)-N-[1-[3-Fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]isoquinoline-5-sulfonamide 553650-56-9P, (S)-(E)-2-(4-Chlorophenyl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-57-0P, (S)-5'-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-2,2'-bithiophene-5-sulfonamide 553650-58-1P, (S)-6-(Dimethylamino)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553650-59-2P,

(S)-N-[1-[3-Fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]quinoline-8-sulfonamide 553650-60-5P, (S)-6-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1-benzothiophene-2-sulfonamide 553650-61-6P, (S)-5-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1-benzothiophene-2-sulfonamide 553650-63-8P 553650-66-1P, (S)-N-[1-[2'-(Aminosulfonyl)-3-fluoro-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-6-chloro-1-benzothiophene-2-sulfonamide 553650-69-4P, (S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-(3-fluoro-2'-nitro-1,1'-biphenyl-4-yl)-2-oxopyrrolidin-3-yl]ethenesulfonamide 553650-70-7P 553650-71-8P 553650-85-4P, (S)-4-Cyano-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]benzenesulfonamide 553650-87-6P, (S)-6-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1-benzofuran-2-sulfonamide 553650-88-7P, (S)-6-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]thieno[3,2-b]pyridine-2-sulfonamide 553650-89-8P, (S)-5-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]thieno[3,2-b]pyridine-2-sulfonamide 553650-90-1P, (S)-(1E)-2-(5-Chlorothien-2-yl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]prop-1-ene-1-sulfonamide 553650-96-7P 553650-97-8P 553650-98-9P 553650-99-0P 553651-00-6P 553651-01-7P 553651-05-1P, (S)-3-(Aminomethyl)-N-[1-[3-

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]benzenesulfonamide 553651-06-2P, (S)-4-(Aminomethyl)-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]benzenesulfonamide 553651-08-4P, (S)-6-Chloro-N-[1-[4-(2,4-

dimethoxypyrimidin-5-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-09-5P, (S)-6-Chloro-N-[1-[2-fluoro-4-(pyridin-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-10-8P, (S)-6-Chloro-N-[1-[2-fluoro-4-(6-methoxypyridin-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-11-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-propylpyridin-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-12-0P, (S)-6-Chloro-N-[1-[2-fluoro-4-[6-(methylthio)pyridin-3-yl]phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-13-1P, (S)-N-[1-[4-(5-Bromopyridin-3-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]-6-chloronaphthalene-2-sulfonamide 553651-14-2P, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-methoxypyridin-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-15-3P, (S)-6-Chloro-N-[1-[2-fluoro-4-(pyrimidin-5-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-16-4P, (S)-N-[1-[3'-(Aminomethyl)-3-fluoro-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-6-chloronaphthalene-2-sulfonamide 553651-17-5P, (S)-6-Chloro-N-[1-[2-fluoro-4-(3-furyl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-18-6P, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-methylthien-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-19-7P, (S)-6-Chloro-N-[1-[2-fluoro-4-(thien-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-20-0P, (S)-6-Chloro-N-[1-[2-fluoro-4-(5-methylthien-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-21-1P, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-methylthien-3-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-22-2P, (S)-6-Chloro-N-[1-[2-fluoro-4-(3-formylthien-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-23-3P, (S)-6-Chloro-N-[1-[4-(5-chlorothien-2-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-24-4P, (S)-6-Chloro-N-[1-[4-(3,5-dimethylisoxazol-4-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-25-5P, (S)-6-Chloro-N-[1-[2-fluoro-4-(5-methyl-2-furyl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-26-6P, (S)-6-Chloro-N-[1-(3-fluoro-1,1'-biphenyl-4-yl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-28-8P 553651-29-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1-oxidopyridin-4-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-30-2P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1-methyl-1H-imidazol-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-32-4P, (S)-6-Chloro-N-[1-[4-(2-chloropyridin-3-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-35-7P, (S)-6-Chloro-N-[1-[4-(2-cyanopyridin-3-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-36-8P, (S)-(E)-N-[1-[4-(3-Chloropyridin-4-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]-2-(5-chlorothien-2-yl)ethenesulfonamide 553651-37-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-(pyrimidin-2-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-38-0P, (S)-6-Chloro-N-[1-[4-(3-chloropyridin-2-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-39-1P, (S)-6-Chloro-N-[1-[4-(3-Chloropyridin-4-yl)-2-fluorophenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-41-5P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1-methyl-1H-imidazol-4-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide formate

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
553651-42-6P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1-methyl-1H-imidazol-5-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-43-7P, (S)-2-(5-Chlorothien-2-yl)-N-[1-[3-fluoro-2'-

(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]-1,3-thiazole-5-sulfonamide 553651-45-9P, (S)-5-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]thieno[3,2-b]thiophene-2-sulfonamide 553651-46-0P, (S)-2-Chloro-N-[1-[3-fluoro-2'-(methylsulfonyl)-1,1'-biphenyl-4-yl]-2-oxopyrrolidin-3-yl]thieno[3,2-b]thiophene-3-sulfonamide 553651-49-3P, (S)-6-Chloro-N-[1-(2-fluoro-4-iodophenyl)-2-oxopyrrolidin-3-yl]benzothiophene-2-sulfonamide 553651-50-6P 553651-51-7P, (S)-2-(5-Chloro-2-thienyl)-N-[1-(2-fluoro-4-iodophenyl)-2-oxopyrrolidin-3-yl]ethanesulfonamide 553651-52-8P 553651-53-9P, (S)-(E)-2-(5-Chloro-2-thienyl)-N-[1-(2-fluoro-4-nitrophenyl)-2-oxopyrrolidin-3-yl]ethenesulfonamide 553651-54-0P 553651-55-1P 553651-56-2P, (S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-(4-cyano-2-fluorophenyl)-2-oxopyrrolidin-3-yl]ethenesulfonamide 553651-57-3P, (S)-2-(5-Chlorothien-2-yl)-N-[1-(4-cyano-2-fluorophenyl)-2-oxopyrrolidin-3-yl]ethanesulfonamide 553651-58-4P, (S)-(E)-2-(5-Chloro-2-thienyl)-N-[1-(2-fluoro-4-isopropenylphenyl)-2-oxopyrrolidin-3-yl]ethenesulfonamide 553651-59-5P, (S)-6-Chloro-N-[1-(2-fluorophenyl)-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-61-9P 553651-62-0P 553651-63-1P, (S)-(E)-2-(5-Chloro-2-thienyl)-N-[1-[2-fluoro-4-[1-pyrrolidinylcarbonyl]phenyl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553651-66-4P 553651-67-5P, (S)-4-[3-[[(6-Chlorobenzothien-2-yl)sulfonyl]amino]-2-oxopyrrolidin-1-yl]-3-fluoro-N,N-dimethylbenzamide 553651-68-6P 553651-69-7P,

(S)-4-[3-[[(6-Chlorobenzothien-2-yl)sulfonyl]amino]-2-oxopyrrolidin-1-yl]-3-fluoro-N-isopropyl-N-methylbenzamide 553651-72-2P 553651-73-3P 553651-74-4P 553651-75-5P 553651-76-6P 553651-77-7P, (S)-N-[4-[3-[[(6-

Chlorobenzothien-2-yl)sulfonyl]amino]-2-oxopyrrolidinyl]-3-fluorophenyl]-2-methylpropanamide 553651-78-8P, (S)-(E)-2-(5-Chlorothien-2-yl)-N-[1-[2-fluoro-4-[formyl(isopropyl)amino]phenyl]-2-oxopyrrolidin-3-yl]ethenesulfonamide 553651-79-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-[formyl(isopropyl)amino]phenyl]-2-oxopyrrolidin-3-yl]benzothiophene-2-sulfonamide 553651-80-2P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1H-imidazol-1-yl)phenyl]-2-oxopyrrolidin-3-yl]naphthalene-2-sulfonamide 553651-82-4P, (S)-6-Chloro-N-[1-(2,4-dichlorophenyl)-2-oxopyrrolidin-3-yl]-2-naphthalenesulfonamide 553651-84-6P, (S)-N-[1-(4-tert-Butylphenyl)-2-oxopyrrolidin-3-yl]-6-chloro-2-naphthalenesulfonamide 553651-87-9P, (S)-6-Chloro-N-[1-[2-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-oxopyrrolidin-3-yl]-2-naphthalenesulfonamide 553651-88-0P, (S)-6-Chloro-N-[1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-oxopyrrolidin-3-yl]-2-naphthalenesulfonamide 553651-92-6P 553651-93-7P 553651-96-0P, (S)-(1E)-2-(5-Chlorothien-2-yl)-N-[1-[2-fluoro-4-[(methylsulfonyl)amino]phenyl]-2-oxopyrrolidin-3-yl]prop-1-ene-1-sulfonamide 553651-97-1P, (S)-(E)-N-[1-(4-Acetylphenyl)-2-oxopyrrolidin-3-yl]-2-(5-chlorothien-2-yl)ethenesulfonamide 553651-98-2P 553651-99-3P 553652-01-0P 553652-02-1P, (S)-2-(5-Chlorothien-2-yl)-N-[1-[4-[2-

[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxopyrrolidin-3-yl]ethanesulfonamide 553652-04-3P 553652-06-5P

Karen Cheng

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
553652-08-7P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(factor Xa inhibitor; prepn. of (sulfonylamino)pyrrolidinone factor Xa inhibitors starting from homoserines)
RN 553650-48-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-50-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(dimethylamino)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-53-6 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-57-0 CAPLUS
CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-58-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-(dimethylamino)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-54-7 CAPLUS
CN 2-Benzofuransulfonamide, 5-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-55-8 CAPLUS
CN 5-Isoquinolinesulfonamide, N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-56-9 CAPLUS
CN Ethenesulfonamide, 2-(4-chlorophenyl)-N-[(3S)-1-[3-fluoro-2'-

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-59-2 CAPLUS
CN 8-Quinolinesulfonamide, N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-60-5 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-61-6 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-63-8 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]benzo[b]thiophene-2-sulfonamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 553650-62-7
CMF C24 H23 Cl F N5 O3 S2

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O=CH-OH

RN 553650-66-1 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, N-[(3S)-1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-69-4 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-(3-fluoro-2'-nitro[1,1'-biphenyl]-4-yl)-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-70-7 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3'-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-71-8 CAPLUS
CN [1,1'-Biphenyl]-2-sulfonamide, 4'-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3'-fluoro- (9CI)

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
(CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-85-4 CAPLUS
CN Benzenesulfonamide, 4-cyano-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-87-6 CAPLUS
CN 2-Benzofuransulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-88-7 CAPLUS
CN Thieno[3,2-b]pyridine-2-sulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-89-8 CAPLUS
CN Thieno[3,2-b]pyridine-2-sulfonamide, 5-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553650-90-1 CAPLUS
CN 1-Propene-1-sulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553650-96-7 CAPLUS
CN Carbamic acid, [[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl][(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-97-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-N-[2-(4-morpholinyl)ethyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-98-9 CAPLUS
CN Acetamide, 2-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl][(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
CN [1,1'-Biphenyl]-3-carboxamide, 4'-[(3S)-3-[[(6-chloro-2-naphthalenyl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3'-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-05-1 CAPLUS
CN Benzenesulfonamide, 3-(aminomethyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-06-2 CAPLUS
CN Benzenesulfonamide, 4-(aminomethyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
pyrrolidinyl]amino]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553650-99-0 CAPLUS
CN Glycine, N-[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-00-6 CAPLUS
CN Glycine, N-[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-01-7 CAPLUS

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-08-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(2,4-dimethoxy-5-pyrimidinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-09-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(3-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-10-8 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(6-methoxy-3-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-11-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-propyl-3-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-12-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(6-(methylthio)-3-pyridinyl]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-16-4 CAPLUS
CN 2-Naphthalenesulfonamide, N-[(3S)-1-[3'-(aminomethyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-17-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(3-furanyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-18-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-methyl-2-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-13-1 CAPLUS
CN 2-Naphthalenesulfonamide, N-[(3S)-1-[4-(5-bromo-3-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-6-chloro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-14-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-methoxy-3-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-15-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(5-pyrimidinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-19-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(3-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-20-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(5-methyl-2-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-21-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-methyl-3-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-22-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(3-formyl-2-thienyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-23-3 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(5-chloro-2-thienyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-24-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(3,5-dimethyl-4-isoxazolyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry as shown.



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 553651-29-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-oxido-4-pyridinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-30-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-methyl-1H-imidazol-2-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-25-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(5-methyl-2-furanyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-26-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(3-fluoro[1,1'-biphenyl]-4-yl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-28-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)-, bis(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 553651-27-7
CMF C22 H23 Cl F N5 O3 S2

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-32-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(2-chloro-3-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-35-7 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(2-cyano-3-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-36-8 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-[4-(3-chloro-4-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-37-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(2-pyrimidinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-38-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(3-chloro-2-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-39-1 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(3-chloro-4-pyridinyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-43-7 CAPLUS
CN 5-Thiazolesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-45-9 CAPLUS
CN Thieno[3,2-b]thiophene-2-sulfonamide, 5-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-46-0 CAPLUS
CN Thieno[3,2-b]thiophene-3-sulfonamide, 2-chloro-N-[(3S)-1-[3-fluoro-2'-(methylsulfonyl)[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-41-5 CAPLUS
CN Formic acid, compd. with 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-methyl-1H-imidazol-4-yl)phenyl]-2-oxo-3-pyrrolidinyl]-2-naphthalenesulfonamide (1:1)
(9CI) (CA INDEX NAME)

CM 1

CRN 553651-40-4
CMF C24 H20 Cl F N4 O3 S

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

RN 553651-42-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1-methyl-1H-imidazol-5-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-49-3 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-(2-fluoro-4-iodophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-50-6 CAPLUS
CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-1-(2-fluoro-4-iodophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-51-7 CAPLUS
CN 2-Thiopheneethanesulfonamide, 5-chloro-N-[(3S)-1-(2-fluoro-4-iodophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
RN 553651-52-8 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3R)-1-(2-fluoro-4-nitrophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-53-9 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-(2-fluoro-4-nitrophenyl)-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-54-0 CAPLUS
CN [2,2'-Bithiophene]-5-sulfonamide, 5'-chloro-N-[(3S)-1-(2-fluoro-4-nitrophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-55-1 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-(4-cyano-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-56-2 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-(4-cyano-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-57-3 CAPLUS
CN 2-Thiopheneethanesulfonamide, 5-chloro-N-[(3S)-1-(4-cyano-2-fluorophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-58-4 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-(1-methylethenyl)phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-59-5 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(2-fluorophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-61-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[3-fluoro-4-(4-morpholinyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-62-0 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-63-1 CAPLUS
CN Pyrrolidine, 1-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorobenzoyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-66-4 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-67-5 CAPLUS
CN Benzamide, 4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-68-6 CAPLUS
CN Benzamide, 4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-69-7 CAPLUS
CN Benzamide, 4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N-methyl-N-(1-methylethyl)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-72-2 CAPLUS
CN Acetamide, N-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Double bond geometry as shown.



RN 553651-73-3 CAPLUS
CN Propanamide, N-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-74-4 CAPLUS
CN Propanamide, N-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-75-5 CAPLUS
CN Acetamide, N-[4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-76-6 CAPLUS
CN Propanamide, N-[4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-77-7 CAPLUS
CN Propanamide, N-[4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]-2-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-78-8 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[formyl(1-methylethyl)amino]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-79-9 CAPLUS
CN Benzo[b]thiophene-2-sulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-[formyl(1-methylethyl)amino]phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-80-2 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1H-imidazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-82-4 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-(2,4-dichlorophenyl)-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-84-6 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[4-(1,1-dimethylethyl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-87-9 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(4-methyl-1H-imidazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 553651-88-0 CAPLUS
CN 2-Naphthalenesulfonamide, 6-chloro-N-[(3S)-1-[2-fluoro-4-(1H-pyrazol-1-yl)phenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553651-92-6 CAPLUS
CN Benzamide, 4-[(3S)-3-[(2-amino-2-oxoethyl)[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-93-7 CAPLUS
CN Benzamide, 4-[(3S)-3-[(2-amino-2-oxoethyl)[[(1E)-2-(5-chloro-2-thienyl)ethenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluoro-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-96-0 CAPLUS
CN 1-Propene-1-sulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[2-fluoro-4-[(methylsulfonyl)amino]phenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-97-1 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-(4-acetylphenyl)-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553651-98-2 CAPLUS
CN Acetamide, 2-[[1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl][[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.



RN 553651-99-3 CAPLUS
CN Acetamide, 2-[[1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl][[(1Z)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]- (9CI) (CA INDEX NAME)

Double bond geometry as shown.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553652-01-0 CAPLUS
CN Formic acid, compd. with 2-[[(3S)-1-[2'-(aminosulfonyl)-3-fluoro[1,1'-biphenyl]-4-yl]-2-oxo-3-pyrrolidinyl][(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]acetamide (1:1) (9CI) (CA INDEX NAME)

CM 1

CRN 553652-00-9
CMF C26 H22 Cl F N4 O6 S3

Absolute stereochemistry.



CM 2

CRN 64-18-6
CMF C H2 O2

O═CH—OH

RN 553652-02-1 CAPLUS
CN 2-Thiopheneethanesulfonamide, 5-chloro-N-[(3S)-1-[4-[2-[(dimethylamino)methyl]-1H-imidazol-1-yl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 553652-04-3 CAPLUS
CN 1H-Imidazole-2-methanaminium, N-(2-amino-2-oxoethyl)-1-[4-[(3S)-3-[[[(1E)-2-(5-chloro-2-thienyl)-1-propenyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]-N,N-dimethyl-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 553652-03-2
CMF C25 H29 Cl F N6 O4 S2

Absolute stereochemistry.
Double bond geometry as shown.



CM 2

CRN 71-47-6
CMF C H O2

O=CH-O⁻

RN 553652-06-5 CAPLUS
CN 1H-Imidazole-2-methanaminium, N-(2-amino-2-oxoethyl)-1-[4-[(3S)-3-[[[2-(5-chloro-2-thienyl)ethyl]sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]-N,N-dimethyl-, formate (9CI) (CA INDEX NAME)

CM 1

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

CRN 553652-05-4
CMF C24 H29 Cl F N6 O4 S2

Absolute stereochemistry.



CM 2

CRN 71-47-6
CMF C H O2

O=CH-O⁻

RN 553652-08-7 CAPLUS
CN 1H-Imidazole-2-methanaminium, N-(2-amino-2-oxoethyl)-1-[4-[(3S)-3-[[(6-chlorobenzo[b]thien-2-yl)sulfonyl]amino]-2-oxo-1-pyrrolidinyl]-3-fluorophenyl]-N,N-dimethyl-, formate (9CI) (CA INDEX NAME)

CM 1

CRN 553652-07-6
CMF C26 H27 Cl F N6 O4 S2

Absolute stereochemistry.



CM 2

CRN 71-47-6
CMF C H O2

L3 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)

O=CH-O⁻

IT 553653-26-2P 553653-27-3P
RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
(intermediate; preparation of (sulfonylamino)pyrrolidinone factor Xa inhibitors starting from homoserines)

RN 553653-26-2 CAPLUS
CN Ethenesulfonamide, N-[(3S)-1-[4-(1-bromoethyl)-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-2-(5-chloro-2-thienyl)-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



RN 553653-27-3 CAPLUS
CN Ethenesulfonamide, 2-(5-chloro-2-thienyl)-N-[(3S)-1-[4-[1-(diformylamino)ethyl]-2-fluorophenyl]-2-oxo-3-pyrrolidinyl]-, (1E)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.
Double bond geometry as shown.



REFERENCE COUNT: 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN

ACCESSION NUMBER: 1994:245060 CAPLUS
DOCUMENT NUMBER: 120:245060
TITLE: Beta-carboline derivatives with anticholecystokinin activity, and their preparation, use, and pharmaceutical compositions
INVENTOR(S): Yamada, Koichiro; Hikota, Masataka; Yura, Takeshi; Shikano, Toshiro; Nagasaki, Masaaki
PATENT ASSIGNEE(S): Tanabe Seiyaku Co., Ltd., Japan
SOURCE: Eur. Pat. Appl., 26 pp.
CODEN: EPXXDW
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
EP 572235	A2	19931201	EP 1993-304083	19930526
EP 572235	A3	19940601		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LI, LU, MC, NL, PT, SE				
JP 06041126	A	19940215	JP 1993-123668	19930526
CA 2097112	A1	19931129	CA 1993-2097112	19930527
US 5434148	A	19950718	US 1993-67931	19930527
PRIORITY APPLN. INFO.:			JP 1992-136819 A	19920528

OTHER SOURCE(S): MARPAT 120:245060
GI



I

AB Disclosed are β-carboline derivs. I, wherein R1 is H, alkyl, alkoxy, or OH; R5 is H; or R1R5 is alkylenedioxy; R2 is H, halo, alkoxy, or OH; R3 is H, carbamoylalkyl, alkyl, carboxyalkyl, or alkoxycarbonylalkyl; R4 is H, alkyl, carboxyalkyl, alkoxycarbonylalkyl, alkanoyl, arylcarbonyl, alkanesulfonyl, alkoxycarbonyl, aralkyl, formyl, or dialkylsulfamoyl; and n is 0, 1 or 2; and their pharmaceutically acceptable salts. Also claimed is a process for preparing I by formation of the bridging amide linkage, use of the compds. for prophylaxis or treatment of digestive diseases, and pharmaceuticals containing I. Examples include 85 invention compound syntheses and 48 precursor prepns. Thus, Friedel-Crafts cyclization of 4-MeOC6H4NHC6H4F-4 with oxalyl chloride gave 1-(4-fluorophenyl)-5-methoxy-

Karen Cheng

L3 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
1H-indole-2,3-dione, which reacted with NH2OH.HCl to give the 3-oxime. Hydrogenation of the latter to the 3-amino deriv., and amidation of this with β-carbolin-3-ylcarbonyl chloride, gave I [n = 0, R1 = 5-MeO, R2 = 4-F, R3 = R4 = R5 = H]. The compd. I [n = 0, R3 = Me, other Rs = H] at 10 mg/kg i.v. in rats gave significant inhibition of pancreatic secretion induced by CCK-8 (no addnl. data). I are also said to show low toxicity.
IT 154059-19-5P
RL: PRP (Properties); SPN (Synthetic preparation); PREP (Preparation)
(preparation and absolute configuration of, in preparation of CCK antagonists)
RN 154059-19-5 CAPLUS
CN Benzenesulfonamide, N-[1-(4-fluorophenyl)-2,3-dihydro-5-methoxy-3-methyl-2-oxo-1H-indol-3-yl]-4-methyl-, (R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



L3 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1993:485414 CAPLUS
DOCUMENT NUMBER: 119:85414
TITLE: 1,3,4-Trisubstituted pyrrolidinones as scaffolds for construction of peptidomimetic cholecystokinin antagonists
AUTHOR(S): Flynn, Daniel L.; Villamil, Clara I.; Becker, Daniel P.; Gullikson, Gary W.; Moumni, Chafiq; Yang, Dai Chang
CORPORATE SOURCE: Dep. Med. Chem., Searle Res. Dev., Skokie, IL, 60077, USA
SOURCE: Bioorganic & Medicinal Chemistry Letters (1992), 2(10), 1251-6
CODEN: BMCLE8; ISSN: 0960-894X
DOCUMENT TYPE: Journal
LANGUAGE: English
AB A new series of cholecystokinin (CCK) antagonists are described which utilizes a new 1,3,4-trisubstituted pyrrolidinone as a scaffold for appending specific amino acid R group mimics. Several compds. (including SC-50998) exhibit potent nanomolar IC50 values in a CCK-A receptor binding assay. SC-50998 behaves as a competitive antagonist in vitro and is orally active.
IT 144024-01-1
RL: BIOL (Biological study)
(cholecystokinin A receptors antagonism by, structure in relation to)
RN 144024-01-1 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[(2-naphthalenylsulfonyl)amino]-5-oxo-1-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1992:591677 CAPLUS
DOCUMENT NUMBER: 117:191677
TITLE: Preparation of pyrrolidinonecarboxylic acids and related compounds as cholecystokinin antagonists
INVENTOR(S): Becker, Daniel Paul; Flynn, Daniel Lee; Villamil, Clara Ines
PATENT ASSIGNEE(S): G.D. Searle and Co., USA
SOURCE: PCT Int. Appl., 213 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9210476	A1	19920625	WO 1991-US8648	19911125
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MN, MW, NL, NO, PL, RO, SD, SE, SU, US				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
US 5202344	A	19930413	US 1990-626590	19901211
CA 2097517	A1	19920612	CA 1991-2097517	19911125
AU 9190571	A	19920708	AU 1991-90571	19911125
EP 561941	A1	19930929	EP 1992-901239	19911125
EP 561941	B1	19950104		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
JP 06503827	T	19940428	JP 1991-502321	19911125
ES 2067322	T3	19950316	ES 1992-901239	19911125
US 5314886	A	19940524	US 1992-968617	19921029

PRIORITY APPLN. INFO.: US 1990-626590 A1 19901211
WO 1991-US8648 A 19911125

OTHER SOURCE(S): MARPAT 117:191677
GI



I II

AB Title compds. I [Ar = (substituted) aryl, (substituted) heterocyclyl (substituted) bicyclic hydrocarbyl, etc.; R = C1-8 alkyl where 1 C atom may be replaced by O, (substituted) aryl, -aralkyl; X = bond, NH, O, C1-3 alkylene; n = 0, 1; R1, R1' = H, C1-4 alkyl; m = 0-3; R3 = OH, OR5; R5 = C1-6 alkyl, NR6R7; R6,R7 = H, C1-6 alkyl, NR8R9; R8,R9 = (substituted) C4-6 alkylene; R4 = H, C1-4 alkyl; Y = CO, SO2] were prepared as cholecystokinin (CCK) antagonists useful for treatment of CCK related disorders of the gastrointestinal tract, central nervous system, and appetite regulatory system. Thus, Et 4-amino-5-oxo-1-phenyl-3-pyrrolidinecarboxylate (preparation given) was amidated by 2-naphthoyl chloride

L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)
and the product formed was hydrolyzed to give title compd. II. II had IC50 of 0.015 μM against 125I-CCK-OP binding to rat pancreatic membranes.
IT 144023-98-3P 144023-99-4P 144024-00-0P
144024-01-1P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of, as cholecystokinin antagonist)
RN 144023-98-3 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[[(3,4-dichlorophenyl)sulfonyl]amino]-5-oxo-1-phenyl-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 144023-99-4 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[(2-naphthalenylsulfonyl)amino]-5-oxo-1-phenyl-, 1,1-dimethylethyl ester, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



RN 144024-00-0 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[[(3,4-dichlorophenyl)sulfonyl]amino]-5-oxo-1-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.

Karen Cheng

L3 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



RN 144024-01-1 CAPLUS
CN 3-Pyrrolidinecarboxylic acid, 4-[(2-naphthalenylsulfonyl)amino]-5-oxo-1-phenyl-, cis- (9CI) (CA INDEX NAME)

Relative stereochemistry.



L3 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN (Continued)



L3 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2007 ACS on STN
ACCESSION NUMBER: 1990:118581 CAPLUS
DOCUMENT NUMBER: 112:118581
TITLE: Reactions of methyl esters of substituted 2-imino-3,3,3-trifluoropropionic acids with arylamines
AUTHOR(S): Osipov, S. N.; Chkanikov, N. D.; Kolomiets, A. F.; Fokin, A. V.
CORPORATE SOURCE: Inst. Elementoorg. Soedin, Moscow, USSR
SOURCE: Izvestiya Akademii Nauk SSSR, Seriya Khimicheskaya (1989), (7), 1648-52
CODEN: IASKA6; ISSN: 0002-3353
DOCUMENT TYPE: Journal
LANGUAGE: Russian
OTHER SOURCE(S): CASREACT 112:118581
GI



II

AB Treating PhNHR (R = H, Me) with CF3C(:NR1)CO2Me I (R1 = CF3CO, PhSO2, MeSO2) in khladon 113 6 h at 20° gave 65-70% PhNRC(CF3)(NHR1)CO2Me. Similarly, p-R2C6H4NHR (R = Me2CH, Ph, R2 = H, Me, OMe) and I (R1 as above) gave 15-60% indolinones II. PhNMe2 treated with I (R1 = CF3CO, MeSO2) gave 60 and 53% p-Me2NC6H4C(CF3)(NHR1)CO2Me.

IT 125535-61-7P 125535-62-8P
RL: SPN (Synthetic preparation); PREP (Preparation)
(preparation of)

RN 125535-61-7 CAPLUS
CN Benzenesulfonamide, N-[2,3-dihydro-2-oxo-1-phenyl-3-(trifluoromethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)



RN 125535-62-8 CAPLUS
CN Methanesulfonamide, N-[2,3-dihydro-2-oxo-1-phenyl-3-(trifluoromethyl)-1H-indol-3-yl]- (9CI) (CA INDEX NAME)